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Abstract
Background: Deep brain stimulation (DBS) remains an experimental but promising treatment for patients with severe refractory Gilles de la Tourette syndrome
(TS). Controversial issues include the selection of patients (age and clinical presentation), the choice of brain targets to obtain optimal patient-specific outcomes, and
the risk of surgery- and stimulation-related serious adverse events.
Methods: This report describes our open-label experience with eight patients with severe refractory malignant TS treated with DBS. The electrodes were placedi n
the midline thalamic nuclei or globus pallidus, pars internus, or both. Tics were clinically assessed in all patients pre- and postoperatively using the Modified Rush
Video Protocol and the Yale Global Tic Severity Scale (YGTSS).
Results: Although three patients had marked postoperative improvement in their tics (.50% improvement on the YGTSS), the majority did not reach this level of
clinical improvement. Two patients had to have their DBS leads removed (one because of postoperative infection and another because of lack of benefit).
Discussion: Our clinical experience supports the urgent need for more data and refinements in interventions and outcome measurements for severe, malignant,
and medication-refractory TS. Because TS is not an etiologically homogenous clinical entity, the inclusion criteria for DBS patients and the choice of brain targets
will require more refinement.
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Introduction
Tourette syndrome (TS) is a childhood-onset neuropsychiatric
disorder characterized by multiple motor and vocal tics lasting a
minimum of 1 year. Tic disorders are frequently chronic, if not lifelong
conditions. Usual clinical practice focuses initially on educational and
supportive interventions. In addition, a recent multisite randomized
clinical trial demonstrated the efficacy of comprehensive behavioral
intervention for tics in a subset of pediatric and adult patients.
1,2
Nevertheless, most controlled treatments have focused on pharmaco-
logic interventions. Although valuable in the management of
individuals with TS, pharmacotherapy rarely eradicates tics comple-
tely, and many individuals have residual and clinically impairing
symptoms.
3,4 Furthermore, some of the most effective medications for
reducing tics can be associated with a range of adverse effects, and
there is a small subset of patients who will not respond to either
behavioral or pharmacologic approaches.
3
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tional approach for addressing some of the intractable symptoms of
malignant TS. The stimulation targets that have been used in TS
include: 1) the midline thalamic nuclei, with electrodes positioned at
various points along the anterior–posterior axis (centromedian nucleus,
parafascicular nucleus, and nucleus ventro-oralis internus); 2) the
globus pallidus pars internus (GPi), either in the posteroventrolateral
(somatosensory) region or the anteromedial (limbic) region; 3) the
globus pallidus pars externus; 4) the nucleus accumbens/anterior limb
of the internal capsule; and 5) the subthalamic nucleus (Table 1).
5–42
While many of the TS patients reported in the literature have had
beneficial short-term outcomes following DBS, randomized controlled
studies of larger cohorts have not been performed. Although some
surgeries are free of complications, a number of surgery-related serious
adverse events (e.g. bleeding, infection, hardware malfunction) have
been reported, as well as stimulation-related serious adverse events
(e.g. nausea, eye movement abnormalities, sedation, anxiety, altered
mood, changes in sexual function).
5–42 In general, the degree of tic
improvement appears to be more robust for the thalamic and GPi
targets. However, there is at least one case in which targeting the
nucleus accumbens resulted in a marked improvement in self-injurious
tics.
19
This paper details the outcomes of eight additional patients with
intractable, treatment-refractory TS who were treated with DBS.
These patients had their DBS electrodes inserted at various times
during a 7-year period (2004–2011), employing various targets and
approaches based on the available knowledge at the time of
implantation. Two distinct GPi sites (somatosensory [posteroventral]
vs. limbic [anteromesial]) and midline thalamic sites were targeted.
The initial outcome of the first patient discussed here has been
previously reported.
12
Methods
Patient selection
Each of the patients presented had severe malignant tics that
impaired their quality of life and activities of daily living. Five of the
patients exhibited self-injurious tics that either resulted in or
threatened permanent neurologic injury. The decision to treat was
taken on a case-by-case basis based on clinical necessity. Although we
did not have a priori inclusion and exclusion criteria, all patients were
required to have exhausted at least three known treatment options,
including adequate trials with both a typical and atypical neuroleptic.
The treatments had to be administered in adequate dosages and for at
least 6 months.
43 Candidates could not have medical, neurologic, or
psychiatric conditions that may have increased the risk of the
procedure, precluded full participation (during the procedure or
follow-up), or compromised the accuracy of the outcome assessment
measures.
43,44 Four of the patients were >25 years of age at the time of
the surgery and in only three patients was there a documented failed
treatment trial with an a-adrenergic agonist. The decision to not
require a failed trial with an a-adrenergic agonist was based on a
clinical judgment that the length of time needed to complete an
adequate trial (>12 weeks) placed the individual at undue risk of
permanent injury, and also the consideration that the degree of
improvement, even if the trial was successful, would not be sufficient to
reduce the risk of self-injury. Patient inclusion was based on the
consensus of clinicians and the patient that the symptoms and their
associated impairment were severe enough to justify surgery as a
medical necessity.
Prior to surgery, the patients were evaluated by the team at Yale
(M.G.M., R.A.K, A.L.-W.) as well as by the surgeons and other
knowledgeable professionals (A.C.J.L. at Yale and New York College
of Medicine; R.L.A. at Mt. Sinai and Beth Israel Deaconess Medical
Center; and A.Y.M. and M.H.P. at North Shore-Long Island Jewish
Health System). Comorbid conditions and other psychopathology and
psychosocial factors were also assessed. Efforts were made to address
any psychosocial issues that could affect patient participation and
assessment prior to the surgical intervention, but no formal protocol
was followed.
Surgical technique
Frame-based stereotactic targeting employing MRI (Magnetic
Resonance Imaging) with or without CT (Computed Tomography)
was used in each case. The stereotactic coordinates for the targeted
anatomic structure were based on the best available data.
45–50 Typically,
the initial coordinates, derived relative to the intercommissural plane,
were then adjusted by direct visualization on the MRI, with or without
the assistance of digital overlays of the Schaltenbrand and Wahren Atlas.
Implantation trajectories were planned to avoid sulci and cortical vessels.
Intraoperative macrostimulation was performed to assess for adverse
events with the exception of one patient (subject 7), who was
consciously sedated throughout his second and third surgeries.
During test stimulation the patients were asked to report any unwanted
side effects, including but not limited to muscle spasms, persistent
spontaneous sensations, pain, dizziness, and double vision. The
implanted electrodes were secured to the skull employing accepted
techniques and were connected to implantable pulse generators on the
same day or shortly thereafter.
Postoperative management
Postoperative adjustments were performed by a DBS-trained
clinician. The first session occurred 10–14 days following electrode
implantation. A range of pulse widths (60–210 microseconds),
stimulation rates (60–200 Hz), and electrode combinations were
tested. Both monopolar and bipolar arrays were programmed
empirically with the goal of achieving the greatest possible tic
reduction with minimal side effects. Stimulation amplitudes varied
from 0.1 to 5 V. Programming sessions were performed as needed,
typically on a monthly basis for the first year and every 3–6 months
thereafter. A summary of the active DBS contacts and lead locations is
provided in Table 2.
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Columbia University Libraries/Information Services 2Table 1. Published Studies on Deep Brain Stimulation in Tourette Syndrome
Target Study No. Patients Follow-up, Months Tic Improvement
(YGTSS or MRVRS), %
Midline thalamus
(CM–Pf/Voi, CM–Pf)
Visser-Vandewalle (2003)
5 3 12, 8, 60 90, 72, 83
Ackermans et al. (2006)
10
Ackermans et al. (2007)
11
1 (CM–PF/Voi)
1 (CM–PF and
postroventrolateral
GPI)
12, 12 Tic 20 3 min,
Tic 28 2 min
Bajwa et al. (2007)
12 12 4 6 6
Maciunas et al. (2007)
14 5 3 40 (Mean)
Servello et al. (2008)
17 18 3–18 65 (Mean)
Shields et al. (2008)
20 13 4 6
Vernaleken et al. (2009)
21 1 Not reported 36
Porta et al. (2009)
25
Porta et al. (2012)
34
15–18 24, 60–72 long-
term follow-up
(same cases)
52 (Mean)
41, 33, 32, 18, 1
Servello et al. (2009)
26 4 10–26 Slight to modest
improvement
Idris et al. (2010)
28 1 2 Not reported
Marceglia et al. (2010)
29 7 6–24 33 (Mean)
Ackermans et al. (2011)
30 6 12 49 (Mean)
Lee et al. (2011)
32 11 8 5 8
Kuhn et al. (2012)
35 2 12 75 and 100
Savica et al. (2012)
36 3 12 70 (Mean)
Maling et al. (2012)
37 5 4–6 41, 33, 32, 18, 1
Okun et al. (2013)
41 5 6 19 (Mean)
GPi Deidrerich et al. (2005)
6 1 14 47–76
Gallagher et al. (2006)
9 1 Several Disappearance of tics
Ackermans et al. (2006)
10 1 (CM–Pf and
posteroventral GPi)
12 Tics 28 2/min
Shahed et al. (2007)
15 16 8 4
Dehning et al. (2008)
16 11 2 8 8
Dueck et al. (2009)
22 1 12 No improvement
Martı ´nez-Ferna ´ndez et al. (2011)
31 5 (one subject had
both), 3
(posteroventral), 3
(anteromedial)
3–24 32, 19, 14, 63, 32, 19
Cannon et al. (2012)
33 11 (anteromedial) 4–30 51
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The Diagnostic and Statistical Manual, 4th edition, Text Revised (DSM-IV-
TR) criteria for TS and comorbid diagnosis were used in this study to
establish an official diagnosis.
51 We administered additional rating
scales at baseline, including the Yale Global Tic Severity Scale
(YGTSS),
52 the Yale–Brown Obsessive–Compulsive Scale,
53 the
Hamilton Depression Rating Scale,
54 and the Hamilton Anxiety
Rating Scale.
55 These assessments were also conducted at various
intervals from 1 month to 6 years after surgery. Marked improvements
were defined as more than 50% improvement in the Total Tic Score
on the YGTSS (range 0–50). These evaluations were not performed in
a scripted fashion as the DBS therapy was not provided as part of a
prospective trial, but rather on a humanitarian basis.
Results
The clinical characteristics of the eight patients with TS at baseline
are summarized in Table 3. As detailed in Table 3, three of the
patients under the age of 25 years had severe malignant self-injurious
tics. Baseline characteristics of tics and associated symptoms, together
with follow-up evaluations for the eight subjects, are detailed in Table
4. We observed significant reduction in tic severity in three TS patients
(subjects 1, 6 and 8; see Supplementary Materials). The range of
improvement in the YGTSS Total Tic Score for the entire group was
0–85%. The mean percent improvement was 45%, and the median
value was between 20% and 44%.
Two of eight subjects have had their electrodes removed. In one this
was because of postoperative infection (subject 2), and in the other
because of lack of therapeutic benefit after 3 years of stimulation
(subject 3) (see Supplementary Materials for presentations of each
case). At present, one individual has turned off his electrodes but
continues to show a clear benefit (tic reduction) despite a gradual
worsening of his overall neurologic status (subject 1, see below and
Supplementary Materials).
Discussion
There are many unknowns when considering DBS for TS. These
include the optimal target, the best indications for surgery, the optimal
stimulation parameters, the optimal approach to assess social status,
and the potential for social reintegration postsurgery.
41,43,44,56–58
Patient selection
In this series, the two youngest patients (subjects 6 and 8) benefited
the most from surgery and, thus far, these two patients have also been
most successful in resuming a reasonably ‘normal’ life, with good to
excellent reintegration into society. These individuals have also been
successfully withdrawn from psychoactive medications, thus freeing
them from potential side effects. The third individual (subject 1) who
Table 1. Continued
Target Study No. Patients Follow-up, Months Tic Improvement
(YGTSS or MRVRS), %
Dong et al. (2012)
39 2 right GPi only
(posteroventral)
12 59 and 53
Massano et al. (2013)
42 1 (anteromedial) 3, 12, 24 61
CM–Pf and/or GPi
(anteromedial)
Houeto et al. (2005)
7 12 4 8 2
Welter et al. (2008)
18 3 20, 27, 60 65–96
GPe Piedimonte et al. (2013)
40 1 3 ,6 ,2 4 3 9
A/C – NA Flaherty et al. (2005)
8 11 8 2 5
Kuhn et al. (2007)
13 13 0 4 1
Zabek et al. (2008)
19 12 8 8 0
Neuner et al.(2009)
24 13 6 4 4
Burdick et al. (2010)
27 1 39 15% worse
Sachdev et al. (2012)
38 18 5 7
STN Martinez-Torres et al. (2009)
23 11 2 7 6
Abbreviations: A/C, Anterior Limb of Internal Capsule; CM–Pf, Centromedial–Parafascicular Complex; GPe, Globus Pallidus, Pars Externus; GPi, Globus Pallidus, Pars
Internus; MRVRS, Modified Rush Videotape Rating Scale; NA, Nucleus Accumbens; STN, Subthalamic Nucleus; Voi, Ventralis Oralis; YGTSS, Yale Global Tic Severity
Scale.
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Patient Location Identification of the Anatomic Target DBS Settings
1
a Thalamus Leksell frame, MRI intraoperative guidance,
general anesthesia (propofol),
macrostimulation used, no microelectrode
recording
*R 5-7+, 2.5 V, 210
ms, 185 Hz
X (mm lateral AC-PC)55 *L 1-3+, 2.35 V, 180
ms, 185 Hz
Y (mm posterior AC-PC)54
Z (mm beneath AC-PC)50
GPi (posteroventral/sensorimotor) *R 5-C+, 1.0 V, 120
ms, 130 Hz
X (mm lateral to intercommissural)517 *L 1-2+, 1.0 V, 120 ;
ms, 130 Hz
Y (mm anterior to mid-commissural)54
Z (mm deep to mid-commissural)55
2
b Thalamus Leksell frame, MRI intraoperative guidance,
deep sedation, macrostimulation used, no
microelectrode recording
NA
X (mm lateral AC-PC)55
Y (mm posterior AC-PC)54
Z (mm beneath AC-PC)50
3
c Thalamus Leksell frame, MRI intraoperative guidance,
deep sedation, macrostimulation used, no
microelectrode recording
NA
X (mm lateral AC-PC)55
Y (mm posterior AC-PC)54
Z (mm beneath AC-PC)50
4 GPi (posteroventral/sensorimotor) Leksell frame, MRI intraoperative guidance,
deep sedation, macrostimulation used, no
microelectrode recording
R 2-C+, 2. 5 V, 90 ms,
185 Hz
X (mm lateral to intercommissural)517 L 2-C+, 2.0 V, 90 ms,
185 Hz
Y (mm anterior to mid-commissural)54
Z (mm deep to mid-commissural)55
5 GPi (posteroventral/sensorimotor) Leksell frame, MRI intraoperative guidance,
deep sedation, macrostimulation used, no
microelectrode recording
R 4+6-5-7+, 2.1 V,
180 ms, 185 Hz
X (mm lateral to intercommissural)517 L 2-1-0-C+, 2.1 V,
180 ms, 185 Hz
Y (mm anterior to mid-commissural)54
Z (mm deep to mid-commissural)55
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Patient Location Identification of the Anatomic Target DBS Settings
6 Thalamus Leksell frame, MRI/CT fusion, procedure
performed under local anesthesia with
dexmedetomidine used for sedation
R 1-C+, 3.0 V, 90 ms,
130 Hz
X (mm lateral AC-PC) 55 L 1-C+, 3.2 V, 90 ms,
130 Hz
Y (mm posterior AC-PC) 5 4
Z (mm beneath AC-PC) 5 0
Physiologic confirmation with
microelectrode recording and
macrostimulation
7 GPi, anterior mesial (limbic) Leksell frame, MRI intraoperative guidance,
sedation with dexmedetomidine/propofol,
physiologic confirmation with
microelectrodes recording only
*R 1-C+, 3.0 V, 150
ms, 90 Hz
X (mm lateral to intercommissural)514 *L 1-C+, 2.5 V, 180
ms, 120 Hz
Y (mm anterior to mid-commissural)518
Z (mm deep to mid-commissural)55
Thalamus *R 11-C+, 2.0 V, 60
ms, 120 Hz
X (mm lateral AC-PC)56 *L 9-10-C+, 3.0 V, 60
ms, 120 Hz
Y (mm posterior AC-PC)53
Z (mm beneath AC-PC)50
GPi (posteroventral/sensorimotor) R 8-C+, 2.5 V, 90 ms,
185 Hz
X (mm lateral to intercommissural)517 *L 8-C+, 2.5 V, 90 ms,
180 Hz
Y (mm anterior to mid-commissural)54
Z (mm deep to mid-commissural)55
8 Thalamus Leksell frame, MRI/CT fusion, procedure
performed under general anesthesia with
propofol and remifentanil
R C+1-, 2.1 V, 90 ms,
130 Hz
X (mm lateral AC-PC)55 L C+1-, 1.9 V, 90 ms,
130 Hz
Y (mm posterior AC-PC)54
Z (mm beneath AC-PC)50
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virtually tic free for significant periods of time. His disability is a
consequence of permanent and progressive spinal injury secondary to
an extremely forceful whole-body and head-snapping tic.
12 The
forcefulness of this malignant tic has not been lessened by DBS, but its
frequency has been markedly reduced despite the fact that his
electrodes have been turned off for more than 8 months (see
Supplementary Materials, subject 1). While these results may argue
for earlier surgical intervention, it is also worth noting that subject 1
has more recently experienced a failure of his GPi leads because of
wire fractures resulting from the forceful head snapping. These
observations, albeit in a small number of patients, mirror the published
experiences with DBS at the globus pallidus for primary generalized
dystonia.
59,60 Here, too, younger patients and those who had not yet
developed secondary skeletal changes responded more quickly and
more robustly to DBS.
In typical TS, tics usually improve by 20 years of age, an
observation that is often cited to support the view that surgery should
not be considered prior to 25 years of age.
43,61 However, it is
important to note that TS is a heterogeneous clinical entity and that
the prevalence and severity of tics and the behavioral and emotional
comorbidities observed in TS are both higher in younger patients.
62,63
In addition, tics and comorbidities in young people with severe
refractory TS often have a strong association with difficulties
encountered in remaining in school and maintaining normal peer
relationships. It is also the case that younger patients are less likely to
have sustained significant physical injury because of their tics. These
observations suggest that surgical intervention prior to 25 years of age
may be indicated in highly selected patients. Our current view is that a
strict cut-off for eligibility based on age alone may exclude reasonable
candidates, and that as in Parkinson’s disease, age should be just one of
many factors considered when determining an individual patient’s
surgical candidacy.
Target
In four patients, the tics virtually disappeared for 10–14 days
immediately after surgery. In one patient (subject 1) the midline
thalamic site was the target and in three patients (subjects 4, 5, and 7)
the GPi (two sensorimotor and one limbic) was the target. This
disappearance of tics might be attributable to the immediate trauma of
the electrode placement (the so-called microlesion effect).
Alternatively, it might represent a placebo response. Regardless of
the underlying cause, in our experience this immediate response is not
indicative of a long-term improvement in tic symptoms.
In the current case series, we report significant reductions in tic
severity in three TS patients (subjects 1, 6, and 8) with electrode
placement in the midline thalamic nuclei. Servello et al. reported a
similar response to DBS (although to differing degrees) in 18 similarly
treated patients with severe TS.
17 Subject 1 showed a further
significant benefit with the placement of a second set of electrodes in
the sensorimotor GPi. Indeed, this patient experienced periods during
which he reported being virtually tic free for the first time in more than
40 years. The other patients had disappointing outcomes from their
surgeries. However, a longer follow-up interval is needed in at least one
patient (subject 7, who had DBS electrodes placed in both GPi sites as
well as in the midline thalamic nuclei) before we can make this
statement with certainty.
A ‘definitive neuroanatomic target’ for TS DBS has not yet
emerged. The reasons for this are many. First, the specific neuronal
circuitry underlying TS is only partially known.
64–71 In fact, it is not
known if the pathophysiology of TS is the same for all patients, or if
different types of TS patients have similar or dissimilar pathophysiol-
ogies requiring distinct neuromodulatory strategies. This is especially
true for many of the patients in this series, given their severe, refractory
tics, which often failed to show the typical bouts during the course of a
day, or alternatively the waxing and waning course of weeks to
months. Compounding these gaps in our knowledge is a lack of
representative animal models for TS.
72 Finally, the best location for
stimulation within each target (i.e. thalamus or GPi) may be very
specific, and to date we are unable to refine the target physiologically
as is the case for Parkinson’s disease.
50,73
A prevailing model of TS and other hyperkinetic movement
disorders (including dystonia and chorea) implicates a low firing rate in
output neurons of the GPi as a pathophysiologic hallmark.
74,75
However, recent observations suggest that the GPi activity seen in
dystonia and tic disorders may be similar to that encountered in
Table 2. Continued
Patient Location Identification of the Anatomic Target DBS Settings
Physiologic confirmation with
microelectrode recording and
macrostimulation
Abbreviations: AC, Anterior Commissural; DBS, Deep Brain Stimulation; GPi, Globus Pallidus Pars Internus; PC, Posterior Commissural; NA: Not Applicable.
The DBS settings show right side (R), left side (L), voltage (V), pulse width (ms), and rate (Hz).
aGPi electrodes are not currently functional secondary to forceful head-snapping tics that led to electrode dysfunction.
bElectrodes were removed because of infection.
cElectrodes were removed because of lack of therapeutic benefit.
*Electrodes are currently turned OFF.
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Subject Sex Age
(Years)
Disease
Duration
(Years)
Tic
Symptoms
Typical
Waxing
and
Waning
Course
Self-
Injury
Comorbid
Disorders
Family
History
Living and
Work
Situation
Medication
Before Surgery
Current
Medication
1 M 48 45 Eye blinking,
violent head
jerks,
throwing
elbow against
ribs,
abdominal
tensing,
snapping,
grunting,
screeching,
coprolalia
No Yes,
slamming
forearm
against
forehead
OCD (mild
to
moderate),
depression
No Separated,
employed
part time
Haloperidol,
pimozide,
risperidone,
clonidine,
fluoxetine,
clonazepam,
pergolide
Haloperidol,
fluoxetine
gabapentin,
tizanidine,
diazepam,
temazepam,
aspirin
2
a M 44 41 Eye
movements,
facial tics,
head jerking
and snapping,
shoulder
shrugs,
grunting,
throat
clearing
Yes Yes, skin
picking
OCD
(severe)
Yes Unmarried,
self-
employed
Pimozide,
risperidone,
olanzapine,
quetiapine,
fluoxetine,
fluvoxamine,
sertraline,
clomipramine,
clonazepam
Sertraline,
clonazepam
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8Table 3. Continued
Subject Sex Age
(Years)
Disease
Duration
(Years)
Tic
Symptoms
Typical
Waxing
and
Waning
Course
Self-
Injury
Comorbid
Disorders
Family
History
Living and
Work
Situation
Medication
Before Surgery
Current
Medication
3
b M 37 27 Head and
neck
movements,
body jerking,
shifting body
position,
tongue
movements,
hand and arm
tensing,
bumping
objects into
teeth, toe
curling,
diaphragmatic
dystonic tics
limiting ability
to breathe
No No OCD,
attention-
deficit
disorder,
anxiety
symptoms
No Unmarried,
employed
Haloperidol,
pimozide,
clonidine,
fluoxetine,
sertraline,
clonazepam
Clonidine,
clonazepam,
4 M 42 38 Facial
grimacing,
flopping
hands in
front of face,
pointing
finger back
and front,
chest
rubbing,
grunting,
yelling,
whistling,
curse words
No No OCD,
history of
ADHD
No Unmarried,
unemployed
Haloperidol,
pimozide,
clonazepam,
methylphenidate
Clonazepam
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9Table 3. Continued
Subject Sex Age
(Years)
Disease
Duration
(Years)
Tic
Symptoms
Typical
Waxing
and
Waning
Course
Self-
Injury
Comorbid
Disorders
Family
History
Living and
Work
Situation
Medication
Before Surgery
Current
Medication
5 M 24 15 Head jerks,
snapping arm
against side,
kicking,
licking items,
head
grabbing,
copropraxia,
loud
screaming,
sniffing
Yes Yes,
punching,
hitting
himself
OCD Yes Married, one
child,
unemployed
Haloperidol,
pimozide,
risperidone,
fluphenazine,
clonidine,
fluvoxamine,
imipramine,
nortriptyline,
clonazepam,
pergolide
Clonazepam,
quetiapine,
zolpidem,
topiramate,
nicotine
patches,
ketamine,
opiates
6 M 16 13 Eye blinking,
head and
shoulder
jerking, head
bobbing,
flexion and
extension of
arms and
fingers,
spinning in
place, throat
clearing,
coprolalia
Yes No ADHD No Unmarried,
high-school
student
Risperidone,
aripiprazole,
ziprasidone,
sertraline,
tetrabenazine,
methylphenidate,
topiramate
None
M
o
t
l
a
g
h
M
G
,
S
m
i
t
h
M
E
,
L
a
n
d
e
r
o
s
-
W
e
i
s
e
n
b
e
r
g
e
r
A
,
e
t
a
l
D
e
e
p
B
r
a
i
n
S
t
i
m
u
l
a
t
i
o
n
f
o
r
T
o
u
r
e
t
t
e
S
y
n
d
r
o
m
e
T
r
e
m
o
r
 
a
n
d
 
O
t
h
e
r
 
H
y
p
e
r
k
i
n
e
t
i
c
 
M
o
v
e
m
e
n
t
s
h
t
t
p
:
/
/
w
w
w
.
t
r
e
m
o
r
j
o
u
r
n
a
l
.
o
r
g
T
h
e
 
C
e
n
t
e
r
 
f
o
r
 
D
i
g
i
t
a
l
 
R
e
s
e
a
r
c
h
 
a
n
d
 
S
c
h
o
l
a
r
s
h
i
p
C
o
l
u
m
b
i
a
 
U
n
i
v
e
r
s
i
t
y
 
L
i
b
r
a
r
i
e
s
/
I
n
f
o
r
m
a
t
i
o
n
 
S
e
r
v
i
c
e
s
1
0Table 3. Continued
Subject Sex Age
(Years)
Disease
Duration
(Years)
Tic
Symptoms
Typical
Waxing
and
Waning
Course
Self-
Injury
Comorbid
Disorders
Family
History
Living and
Work
Situation
Medication
Before Surgery
Current
Medication
7 M 19 11 Dystonic
posturing,
exclusively
left-sided tics
and self-
injurious
behaviors
such as
poking left
cornea and
pulling on left
eye lid,
repeating
single words
or syllables
No Yes
poking left
eye and
pulling on
left eye
lid, left
cheek
biting
OCD,
some
symptoms
of ADHD
No Unmarried,
unemployed
Haloperidol,
risperidone,
aripiprazole,
fluphenazine,
sertraline,
clonazepam,
tetrabenazine,
guanfacine,
topiramate,
etanercept, N-
acetyl cysteine
Haloperidol,
clonazepam,
clonidine,
clonazepam,
sertraline,
carbamazepine
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1Table 3. Continued
Subject Sex Age
(Years)
Disease
Duration
(Years)
Tic
Symptoms
Typical
Waxing
and
Waning
Course
Self-
Injury
Comorbid
Disorders
Family
History
Living and
Work
Situation
Medication
Before Surgery
Current
Medication
8 M 17 13 Atypical long
bouts of
severe tics
(20 minutes
to 1 hour)
interspaced
with long tic-
free periods,
tics include
opening
mouth wide,
arm and
shoulder
movements,
head and
neck jerks,
rapidly
shaking head
from side to
side, gyrating
head, arching
back, flexion
and
extension of
arms one
side at a time
No Yes,
pounding
of chest,
punching
forehead
OCD, mild
depression,
some
symptoms
of general
anxiety
disorder
Yes for
OCD
Unmarried,
student
Pimozide,
risperidone,
ziprasidone,
aripiprazole,
fluphenazine,
clonidine,
guanfacine,
fluoxetine,
clonazepam,
topiramate
None
Abbreviations: ADHD, Attention-Deficit Hyperactivity Disorder; M, Male; OCD, Obsessive–Compulsive Disorder.
Positive family history: a first-degree (parent, sibling, child) or second-degree (grandparent, aunt, uncle, nephew, niece, half-sibling or a grandchild) relative with a chronic tic disorder. For additional
clinical details, see Supplementary Materials.
aThe electrodes removed due to side effect of infection.
bThe electrodes removed due to a lack of therapeutic benefit.
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2Parkinson’s disease
75–79 and, if true, this could challenge existing
physiologic models. More data regarding TS physiology are needed
before definitive conclusions can be drawn.
Because of the wide interpatient variability in specific tic symptoms
and comorbidities, it still seems appropriate to consider multiple
potential targets for DBS and to select targets based on the specific
clinical characteristics of each patient. Another important factor that
may complicate the interpretation of surgical results is that the amount
of electrical energy delivered to a target can be very different from one
patient to another, and even between hemispheres for the same
patient. In some studies, the current intensity and spread have been so
high that it is doubtful whether the effects of DBS are restricted to the
specific target area.
Postoperative complications
In our case series, one patient (subject 2) developed an infection
secondary to picking at the incision sites. Interestingly, in one recent
study patients with TS were found to have a higher incidence of
infectious complications following DBS than patients with Parkinson’s
disease or dystonia.
80 The basis of this increase is unknown, but
conceivably could be related to host-specific immune factors as there is
a growing body of evidence implicating immune dysregulation in TS
patients.
81
Programming
In addition to careful intraoperative targeting, thoughtful and labor-
intensive programming of the stimulators is very important to
achieving optimal clinical outcomes (see case material for subject 4).
The potential need for frequent programming should be considered
when choosing candidates for surgery, and families need to be fully
apprised of this reality preoperatively. Although a monthly checkup for
optimization and programming following DBS (for the first 6 months)
is a reasonable standard in movement disorders, in our experience a
more flexible schedule can be necessary for TS patients. Reasons for
this include natural symptom fluctuations and variability in patients’
responses to treatment and expectations. We had similar programming
experiences to Porta et al.
25
Confounding factors of the present report include multiple surgeons
(three surgeons in five different centers) employing varied techniques,
as well as the use of unblinded assessments. At the present time there is
no consensus regarding the use of DBS in TS, although most experts
believe it should be used as a last resort in a small subset of individuals
who have severe, self-injurious tics or tics that are both refractory to
treatment and severely impair quality of life. Randomized trials
employing blinded ratings of patients treated by experienced DBS
teams are sorely needed.
41 Finally, a deeper understanding of the
circuitry involved in TS may lead to more successful tailored targeting
for patients with refractory and malignant TS. Presently, however,
Table 4. Individual Changes in Severity of Tics and Associated Behaviors in Eight Patients with Tourette Syndrome
Patients Duration of
Follow-up
(Months)
YGTSS* YBOCS*** HDRS HARS
Before
Surgery
At Last
Follow-up**
Before
Surgery
At Last
Follow-up
Before
Surgery
At Last
Follow-up
Before
Surgery
At Last
Follow-up
1 107 36 10 (72%) 29 8 10 15 0 0
2
a 95 41 32 (20%) 15 0 0 0 5 1
3
b 84 43 40 (7%) 20 27 5 4 20 15
4 51 50 40 (20%) 12 10 3 3 4 3
5 8 38 22 (44%) 0 0 4 1 5 3
6 16 46 7 (85%) 5 5 0 0 2 1
7
c 37 25 25 (0%) 0 0 3 15 3 3
8 6 43 14 (67%) 20 22 2 0 3 3
Abbreviations: HARS, Hamilton Anxiety Rating Scale; HDRS, Hamilton Depression Rating Scale; YBOCS, Yale–Brown Obsessive–Compulsive Scale; YGTSS, Yale
Global Tic Severity Scale.
*Total tic severity does not include impairment score and is based on the worst-ever tic severity measured at the time of interview.
**Percent improvement in the YGTSS Total Tic Score.
***Obsessive–compulsive symptom severity is based on the total obsessive–compulsive severity measured at the time of interview.
aElectrodes were removed because of infection.
bElectrodes were removed because of lack of therapeutic benefit.
cThis patient does not have any vocal tics.
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